The effect of RU486 to uterine leiomyomata and adenomyosis

骆永凤, 孙景礼, 范丽环, 刘铁力, 赵春华, 步春游, 秦丽洁, 滕红
In: 中国基层医药 · 2002 · vol. 9(2) , pp. 129–131 · doi:10.3760/cma.j.issn.1008-6706.2002.02.017 · W3031588817
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-17 ⓘ

Mifepristone treatment significantly reduced uterine leiomyoma and adenomyosis volumes by blocking progesterone receptors, with symptoms improving or resolving in adenomyosis patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

目的探讨米非司酮对子宫肌瘤与子宫腺肌病的作用机制及临床治疗效果.方法选择门诊病人,子宫肌瘤病人50例,全部为壁间肌瘤,其直径为3～7 cm,子宫腺肌病10例.按年龄段分成四组,月经干净后第3天开始口服米非司酮25mg,日服1次,连续服用3个月,观察肌瘤大小的变化.此外,采用多点法测定子宫肌瘤、子宫腺肌病及正常子宫肌层组织中孕激素受体含量.结果子宫肌瘤体积于用药第4周开始下降,平均下降了19%(19%±3.6%),第8周平均下降了39.3%(39.3%±5.4%),至12周明显下降,平均下降了48.6%(48.6%±8.7%),统计学处理,差异有显著意义(P＜0.001).从个别病例上观察仅有3例无变化,而4例体积下降72%.各组间差异无显著意义.子宫腺肌病病人子宫体积平均减少了17.6%,统计学处理差异有显著意义(P＜0.05),临床症状减轻或消失.服药3个月后追踪20例病人(18例子宫肌瘤,2例子宫腺肌病),子宫彩超检查显示,子宫与子宫肌瘤体积无增大趋势.子宫肌瘤与子宫腺肌病病人子宫肌层组织内的孕激素受体含量高于正常的子宫肌层组织.结论子宫肌瘤组织与子宫腺肌病病人子宫肌层组织孕激素受体表达高于正常子宫肌层组织,米非司酮阻断孕激素作用,使子宫肌瘤体积和子宫腺肌病病人子宫体积明显缩小,使子宫腺肌病症状减轻或消失.

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK